MDR1-expressing CD4+ T cells with Th1.17 features resist to neoadjuvant chemotherapy and are associated with breast cancer clinical response

• Published in: Journal for immunotherapy of cancer Vol. 11; no. 11; p. e007733
• Main Authors: Di Roio, Anthony, Hubert, Margaux, Besson, Laurie, Bossennec, Marion, Rodriguez, Céline, Grinberg-Bleyer, Yenkel, Lalle, Guilhem, Moudombi, Lyvia, Schneider, Raphael, Degletagne, Cyril, Treilleux, Isabelle, Campbell, Daniel J, Metzger, Séverine, Duhen, Thomas, Trédan, Olivier, Caux, Christophe, Ménétrier-Caux, Christine
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01-11-2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: Adaptive Immunity; Biomarkers; Breast cancer; Breast Neoplasms; Cancer; Cancer therapies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells; Chemotherapy; Clinical/Translational Cancer Immunotherapy; Cytokines; Cytotoxicity; Female; Flow cytometry; Humans; Immunology; Immunotherapy; Life Sciences; Lymphocytes; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Paclitaxel - pharmacology; Paclitaxel - therapeutic use; Software; Th17 Cells; Tumor Biomarkers; Tumor Microenvironment; Tumors; Adaptive Immunity; Tumor Microenvironment; CD4-Positive T-Lymphocytes; Lymphocytes, Tumor-Infiltrating; Tumor Biomarkers
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2023-007733

BackgroundMultidrug resistance-1 (MDR1) transporter limits the intracellular accumulation of chemotherapies (paclitaxel, anthracyclines) used in breast cancer (BC) treatment. In addition to tumor cells, MDR1 is expressed on immune cell subsets in which it confers chemoresistance. Among human T cells, MDR1 is expressed by most CD8+ T cells, and a subset of CD4+ T helper (Th) cells. Here we explored the expression, function and regulation of MDR1 on CD4+ T cells and investigated the role of this population in response to neoadjuvant chemotherapy (NAC) in BC.MethodsPhenotypic and functional characteristics of MDR1+ CD4 Th cells were assessed on blood from healthy donors and patients with BC by flow cytometry. These features were extended to CD4+ Th cells from untreated breast tumor by flow cytometry and RNA-sequencing (RNA-seq). We performed in vitro polarization assays to decipher MDR1 regulation on CD4 Th cells. We evaluated in vitro the impact of chemotherapy agents on MDR1+ CD4+ Th cells. We analyzed the impact of NAC treatment on MDR1+ CD4+ Th cells from blood and tumors and their association with treatment efficacy in two independent BC cohorts and in a public RNA-seq data set of BC tumor biopsies before and after NAC. Finally, we performed single cell (sc) RNAseq of blood CD4+ memory T cells from NAC-treated patients and combined them with an scRNAseq public data set.ResultsMDR1+ CD4 Th cells were strongly enriched in Th1.17 polyfunctional cells but also in Th17 cells, both in blood and untreated breast tumor tissues. Mechanistically, Tumor growth factor (TGF)-β1 was required for MDR1 induction during in vitro Th17 or Th1.17 polarization. MDR1 expression conferred a selective advantage to Th1.17 and Th17 cells following paclitaxel treatment in vitro and in vivo in NAC-treated patients. scRNAseq demonstrated MDR1 association with tumor Th1.17 and Th with features of cytotoxic cells. Enrichment in MDR1+ CD4+ Th1.17 and Th17 cells, in blood and tumors positively correlated with pathological response. Absence of early modulation of Th1.17 and Th17 in NAC-resistant patients, argue for its use as a biomarker for chemotherapy regimen adjustment.ConclusionMDR1 favored the enrichment of Th1.17 and Th17 in blood and tumor after NAC that correlated to clinical response.